KINSON levodopa 100 mg with carbidopa (as monohydrate) 25 mg tablet bottle

Država: Avstralija

Jezik: angleščina

Source: Department of Health (Therapeutic Goods Administration)

Aktivna sestavina:

carbidopa monohydrate, Quantity: 26.9 mg; levodopa, Quantity: 100 mg

Dostopno od:

Alphapharm Pty Ltd

Farmacevtska oblika:

Tablet, uncoated

Sestava:

Excipient Ingredients: povidone; purified talc; sodium starch glycollate; microcrystalline cellulose; quinoline yellow aluminium lake; maize starch; magnesium stearate

Pot uporabe:

Oral

Enote v paketu:

100 tablets

Tip zastaranja:

(S4) Prescription Only Medicine

Terapevtske indikacije:

Treatment of Parkinson's disease and syndrome. It is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. Levodopa/carbidopa is frequently helpful in the management of tremor, dysphagia, sialorrhoea, and postural instability associated with Parkinson's disease and syndrome.

Povzetek izdelek:

Visual Identification: 9mm flat bevelled-edged yellow tablet debossed LC/2 on one side and 'alpha' on the reverse.; Container Type: Bottle; Container Material: HDPE; Container Life Time: 3 Years; Container Temperature: Store below 30 degrees Celsius; Container Closure: Child resistant closure

Status dovoljenje:

Registered

Datum dovoljenje:

1994-07-11

Navodilo za uporabo

KINSON
_levodopa and carbidopa (as monohydrate)_
CONSUMER MEDICINE INFORMATION
WHAT IS IN THIS LEAFLET
This leaflet answers some common
questions about Kinson.
It does not contain all the available
information. It does not take the
place of talking to your doctor or
pharmacist.
All medicines have benefits and
risks. Your doctor has weighed the
risks of you taking Kinson against
the benefits expected for you.
IF YOU HAVE ANY CONCERNS ABOUT
TAKING THIS MEDICINE, TALK TO YOUR
DOCTOR OR PHARMACIST.
KEEP THIS LEAFLET WITH YOUR
MEDICINE.
You may need to read it again.
WHAT KINSON IS USED
FOR
Kinson is used to treat some of the
symptoms of Parkinson's disease.
This is a disease of the nervous
system that mainly affects body
movement. The three main
symptoms are shaking (tremor),
muscle stiffness and slow and
unsteady movement.
People with Parkinson's disease often
walk with a shuffle as they have
difficulty in initiating movement. If
untreated, Parkinson's disease can
cause difficulty in performing normal
daily activities.
Kinson is most helpful in improving
slow movement and muscle stiffness.
It can also be helpful in treating
shaking, difficulty in swallowing,
drooling and unstable posture.
The symptoms of Parkinson's disease
are caused by a lack of dopamine, a
naturally occurring chemical
produced by certain brain cells.
Dopamine sends messages in the part
of the brain that controls muscle
movement.
When too little dopamine is
produced, slowness of movement
results.
Kinson contains two active
ingredients, levodopa and carbidopa.
Levodopa is a chemical closely
related to dopamine which allows the
body to make its own dopamine.
Carbidopa makes sure that enough
levodopa gets to the brain where it is
needed. In many patients, Kinson
reduces some of the symptoms of
Parkinson's disease.
Your doctor may have prescribed
Kinson for another reason.
ASK YOUR DOCTOR IF YOU HAVE ANY
QUESTIONS ABOUT WHY KINSON HAS
BEEN PRESCRIBED FOR YOU.
Kinson is available only with a
doctor's prescription.
Kinson is available only with a
doctor

Lastnosti izdelka

AUSTRALIAN PRODUCT INFORMATION
KINSON
_Levodopa/Carbidopa (as monohydrate) tablets _
1
NAME OF THE MEDICINE
Levodopa and Carbidopa (as monohydrate)
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
KINSON is a combination of levodopa, the metabolic precursor of
dopamine, and carbidopa, an aromatic
amino acid decarboxylase inhibitor, for the treatment of Parkinson’s
disease and syndrome.
Each tablet contains 100 mg of levodopa and 25 mg of carbidopa (as
monohydrate) as the active
ingredients.
Excipients with known effect: sulfites.
For the full list of excipients, see Section 6.1 LIST OF EXCIPIENTS.
_ _
_ _
3
PHARMACEUTICAL FORM
KINSON tablet: yellow, marked “LC|2” on one side, "Alpha" on the
reverse.
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Treatment of Parkinson's disease and syndrome. It is useful in
relieving many of the symptoms of
Parkinsonism, particularly rigidity and bradykinesia.
Levodopa/carbidopa is frequently helpful in the
management of tremor, dysphagia, sialorrhoea, and postural instability
associated with Parkinson's
disease and syndrome.
4.2
DOSE AND METHOD OF ADMINISTRATION
The optimum daily dosage of Kinson must be determined by careful
titration in each patient. Kinson
tablets are available in a 1:4 ratio of carbidopa to levodopa (25
mg/100 mg).
GENERAL CONSIDERATIONS
Dosage should be titrated to individual patient needs and this may
require adjusting both the individual
dose and the frequency of administration.
Studies show that the peripheral dopa decarboxylase is saturated by
carbidopa at approximately 70 to
100 mg daily. Patients receiving less than this amount of carbidopa
are more likely to experience nausea
and vomiting.
Standard antiparkinsonian drugs, other than levodopa alone, may be
continued while Kinson is being
administered, although dosage may have to be adjusted.
USUAL INITIAL DOSAGE
Dosage is best initiated with one tablet of Kinson three times a day.
This dosage schedule provides 75
mg of carbidopa per day. Dosage may be increased by one tablet every
day or every oth